This report provides an in-depth review of the market access environment in Europe’s five biggest pharmaceutical markets (France, Germany, Italy, Spain, and the UK). In what is a rapidly changing field, it charts developments at European as well as national level, and pinpoints areas in which further change is anticipated. The structure of the report mirrors the path to early commercialization of new drugs, with individual chapters addressing health technology assessment, pricing and reimbursement, managed entry agreements, and post-launch procurement, prescribing, and trade issues – all of which can have a significant bearing on market access in the 5EU.

This Datamonitor Healthcare report contains a Strategy module.